A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer

ConclusionsThe JAK1/2 and TBK1 inhibitor momelotinib in combination with erlotinib did not appear to enhance benefit over the historical data of erlotinib monotherapy in patients withEGFR-mutated NSCLC.ClinicalTrials.gov identifierNCT02206763.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research